The reference panel allows for a more precise comparison of analytical performance of molecular IVD assays intended to detect SARS-CoV-2.

If your email program has trouble displaying this email, view as a webpage. FDA Updates SARS-CoV-2 Reference Panel Comparative Data On December 2, 2020, the U.S. Food and Drug Administration (FDA) updated the SARS CoV-2 reference panel comparative data on FDA's website to reflect the latest information. The FDA SARS-CoV-2 reference panel is an independent performance validation step for diagnostic tests of SARS-CoV-2 infection that are being used for clinical purposes. The reference panel allows for a more precise comparison of the analytical performance of different molecular in vitro diagnostic (IVD) assays intended to detect SARS-CoV-2. The FDA provided the panel, comprised of standardized samples, to test developers who are required to assess their test's performance against this panel (or other FDA-recommended reference materials) as a condition of their Emergency Use Authorization (EUA).  See Reference Panel Data Update Questions? If you have questions, please email COVID19DX@fda.hhs.gov.

Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA